Uzm. Dr. Aziz Nazaroğlu
Est-ce votre profil ? Revendiquez-le et vérifiez vos informations.
Revendiquer le profilConfiance
D’où viennent ces informations ?
La source est indiquée à côté de chaque information. Si vous constatez une erreur, vous pouvez suggérer une correction.
- SpécialitéMédecine nucléairesaglik.gov.trD’après la source
- ÉtablissementDr. İsmail Fehmi Cumalıoğlu Şehir Hastanesisaglik.gov.trD’après la source
- Publications10 publicationsORCIDD’après la source
- ORCID0000-0002-3052-9314ORCIDD’après la source
- Dernière synchronisation5 novembre 2026 10:37https://tekirdagsehir.saglik.gov.tr/TR-584399/doktorlarimiz.html#aziz-nazaroglusaglik.gov.tr
Travaux scientifiques
Publications
-
Beyond tumor burden: PET/CT-derived psoas muscle quality and survival outcomes in metastatic NSCLC patients treated with nivolumab.
BMC cancer, 2026
DOI 10.1186/s12885-026-16210-z PMID 42192342 Texte intégral en libre accèsSource : ORCID
-
Incidental Findings on 18F-Fluorocholine PET for Parathyroid Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 2023
Source : ORCID
-
The contribution of PET/MR in benign malignant nodule separation in thyroid incidentalomas detected in FDG PET/CT imaging
European Journal of Nuclear Medicine and Molecular Imaging, 2022
Source : ORCID
-
Using Visual Recognition Based Machine Learning For The Prediction Of Survival In Patients With Colorectal Cancer With Liver Metastasis
European Journal of Nuclear Medicine and Molecular Imaging, 2022
Source : ORCID
-
Can FDG PET Predict Covid 19 Disease Severity and Discharge Time
European Journal of Nuclear Medicine and Molecular Imaging, 2021
Source : ORCID
-
Evaluation of thyroid function in patients receiving Lu-177 DOTATATE treatment
European Journal of Nuclear Medicine and Molecular Imaging, 2021
Source : ORCID
-
Evaluation of treatment efficiency in 301 patients with hyperthyroidism treated with a single dose of I-131 as outpatient
European Journal of Nuclear Medicine and Molecular Imaging, 2021
Source : ORCID
-
The Effectiveness of 177Lu-DOTA TATE in Radioiodine-Refractory Differentiated Thyroid Cancer
European Journal of Nuclear Medicine and Molecular Imaging, 2020
Source : ORCID
-
The effectiveness of 177Lu-DOTATATE in patients with metastatic medullary thyroid cancer
European Journal of Nuclear Medicine and Molecular Imaging, 2020
Source : ORCID
-
The efficacy of Lu177-PSMA treatment at chemotherapy-naive metastatic prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging, 2020
Source : ORCID